We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 3 for:    "Hyperlipoproteinemia type 3"
Previous Study | Return to List | Next Study

DARK STUDY "DysbetalipoproteinemiA and atheRoma Risk" (DARK)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2013 by Hospices Civils de Lyon.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01760265
First Posted: January 4, 2013
Last Update Posted: January 28, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hospices Civils de Lyon
  Purpose

Dysbetalipoproteinemia (type III, Fredrickson's classification) is a rare metabolic disorder. It results from a defect in the clearance of VLDL and chylomicron remnants due to homozygous APOE2 variants or heterozygous APOE mutations, and there is an elevated plasma cholesterol and triglycerides.

As a consequence of the derangements in lipoprotein metabolism, dysbetalipoproteinemia predispose to the premature development of atherosclerosis.

However among this population there is heterogeneity in development of cardiovascular complications and the determinants remain unclear actually.

The aim of the investigators study is to evaluate the intensity of clinical atherosclerosis, and identify its determinants.


Condition
Dysbetalipoproteinemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dysbetalipoproteinemia and Atheroma Risk : Assessment of Cardiovascular Risk in Dysbetalipoproteinemic Patients

Resource links provided by NLM:


Further study details as provided by Hospices Civils de Lyon:

Primary Outcome Measures:
  • Computed tomographic measurements for coronary-artery calcium [ Time Frame: Day one : the coronary calcium score is assessed on the date of measurement ]
    Comparison with eventual previous examinations.


Secondary Outcome Measures:
  • Measurement of carotid intima-media by ultrasonography [ Time Frame: Day one : on the date of measurement ]
    Comparison with eventual previous examinations.

  • Measurement of ankle brachial index [ Time Frame: Day one : on the date of measurement ]
    Comparison with eventual previous examinations


Biospecimen Retention:   Samples With DNA
Lipid, apo E genotype when is necessary to complete the phenotype

Estimated Enrollment: 50
Study Start Date: January 2013
Estimated Study Completion Date: June 2013
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Dysbetalipoproteinemia patients with APOE2/E2 or heterozygous mutation (negative dominance) and hypercholesterolemia, ratio CT VLDL/Tg VLDL >0.40
Criteria

Inclusion Criteria:

- apo E gene sequencing in CBE (Centre de Biologie Est / Hospices Civils de Lyon / France) laboratory in Lyon until December 2012

Exclusion Criteria:

  • age < 40 years
  • refused participation
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01760265


Contacts
Contact: Philippe MOULIN, Pr 4 72 68 13 04 ext +33 philippe.moulin@chu-lyon.fr

Locations
France
Hospices Civils de Lyon - Groupement Hospitalier Est Recruiting
Bron, France, 69100
Contact: Philippe MOULIN    4 72 68 13 04 ext +33    Philippe.moulin@chu-lyon.fr   
Principal Investigator: Philippe MOULIN, Pr         
Sponsors and Collaborators
Hospices Civils de Lyon
Investigators
Principal Investigator: Philippe MOULIN, Pr Hospices Civils de Lyon
  More Information

Responsible Party: Hospices Civils de Lyon
ClinicalTrials.gov Identifier: NCT01760265     History of Changes
Other Study ID Numbers: 1
First Submitted: January 2, 2013
First Posted: January 4, 2013
Last Update Posted: January 28, 2013
Last Verified: January 2013

Keywords provided by Hospices Civils de Lyon:
dysbetalipoproteinemia
artery calcium score
carotid intima media
ankle brachial index
dysbetalipoproteinemic patients

Additional relevant MeSH terms:
Hyperlipoproteinemia Type III
Plaque, Atherosclerotic
Pathological Conditions, Anatomical
Lipid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Hyperlipoproteinemias
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases